Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...

ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...

Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease, with an incidence of 1 or 2 cases per 100,000 persons and a lifetime risk of 1 case per 800 persons.

Correspondence Amyotrophic Lateral Sclerosis Published October 11, 2001 N Engl J Med 2001;345: 1131 - 1132 DOI: 10.1056/NEJM200110113451514 ...